Health Care [ 8/12 ] | Health Care Equipment & Supplies [ 35/74 ]
NYSE | Common Stock
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system.
In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases.
It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors.
The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 19, 25 | -0.40 Increased by +36.51% | -0.39 Decreased by -2.96% |
| Nov 4, 24 | -0.28 Increased by +44.00% | -0.48 Increased by +41.67% |
| Jul 31, 24 | -0.52 Increased by +5.45% | -0.51 Decreased by -1.96% |
| May 1, 24 | -0.70 Decreased by -18.64% | -0.57 Decreased by -22.81% |
| Feb 21, 24 | -0.63 Decreased by -18.87% | -0.55 Decreased by -14.55% |
| Nov 1, 23 | -0.50 Decreased by -11.11% | -0.55 Increased by +9.09% |
| Aug 2, 23 | -0.55 Increased by +33.73% | -0.55 |
| May 3, 23 | -0.59 Decreased by -55.26% | -0.58 Decreased by -1.72% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 105.50 M Increased by +28.09% | -33.58 M Increased by +8.70% | Decreased by -31.83% Increased by +28.72% |
| Sep 30, 24 | 96.67 M Increased by +23.86% | -21.41 M Increased by +29.68% | Decreased by -22.15% Increased by +43.22% |
| Jun 30, 24 | 95.69 M Increased by +19.02% | -50.55 M Decreased by -54.04% | Decreased by -52.82% Decreased by -29.43% |
| Mar 31, 24 | 85.62 M Increased by +15.86% | -40.84 M Decreased by -17.94% | Decreased by -47.70% Decreased by -1.79% |
| Dec 31, 23 | 82.36 M Increased by +15.64% | -36.78 M Decreased by -16.91% | Decreased by -44.65% Decreased by -1.10% |
| Sep 30, 23 | 78.05 M Increased by +9.51% | -30.44 M Decreased by -10.40% | Decreased by -39.01% Decreased by -0.81% |
| Jun 30, 23 | 80.40 M Increased by +10.61% | -32.81 M Increased by +27.94% | Decreased by -40.81% Increased by +34.86% |
| Mar 31, 23 | 73.90 M Increased by +9.19% | -34.63 M Decreased by -743.97% | Decreased by -46.86% Decreased by -689.78% |